Loading...
NPI 1265854855 · Scottsdale, AZ · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Genetic Technological Innovations, LLC is a clinical medical laboratory provider located in Scottsdale, Arizona. This profile covers 82 Medicare and 83 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Genetic Technological Innovations, LLC |
| Address | 13402 N Scottsdale Rd Ste 190 |
| City | Scottsdale |
| State | AZ |
| ZIP | 85254 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 15, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $21.5M |
| Medicaid | $14.5M |
GENETIC TECHNOLOGICAL INNOVATIONS, LLC presents as a high-volume clinical molecular laboratory: its Medicare top codes are dominated by amplified nucleic acid probe techniques (87798 and 87150) and high-volume COVID-related testing (K1034 and U0003 appear in top lists), while Medicaid billing is concentrated in high-throughput SARS‑CoV‑2 detection and specimen collection. The code mix (numerous amplified probe codes, multiplex respiratory panels such as 87637 and 87635, plus molecular pathology interpretation under G0452) indicates the operation provides both large-scale technical testing and downstream molecular interpretation services.
Medicare revenue is concentrated: the top three Medicare codes account for 59.0% of total Medicare revenue, with 87798 ($5.3M, 26.3%), 87150 ($4.7M, 23.2%), and K1034 ($1.9M, 9.4%) driving the bulk of billed services. This concentration suggests the provider’s Medicare business is heavily dependent on a small set of molecular and COVID-related tests rather than a broadly diversified CPT mix.
Medicaid revenue is likewise concentrated, with the top three Medicaid codes accounting for 63.2% of total Medicaid revenue; U0003 ($5.3M, 41.1%), G0483 ($1.9M, 14.8%), and G2023 ($963.7K, 7.4%) are the dominant lines. The Medicaid profile highlights reliance on state-level high-throughput SARS‑CoV‑2 testing and on definitive drug testing services, making Medicaid revenue particularly sensitive to demand shifts in those categories.
The provider’s payer mix shows material business across both government payers: Total Medicare revenue is $21.5M while Total Medicaid revenue is $14.5M, so Medicare is the larger single payer but Medicaid represents a substantial portion of the provider’s public-payer volume. This is not a single-payer operation — analysts should treat changes in either Medicare or Medicaid policy for molecular/COVID or drug-testing codes as potentially impactful.
On competitive standing, GENETIC TECHNOLOGICAL INNOVATIONS is a national outlier on multiple molecular codes: 87798 ranks #6 of 1319 providers nationally (100th percentile, extreme outlier) and 87150 ranks #2 of 190 providers nationally (99th percentile, extreme outlier), while G0452 ranks #1 of 614 providers nationally (100th percentile, extreme outlier). These rankings indicate the organization is a national leader for several amplified-probe molecular services and commands volumes far above typical national peers.
Within Arizona Medicaid, the provider shows state-level dominance on several services: G0483 is #1 of 23 in-state (100th percentile; extreme outlier) and G2023 is #2 of 63 in-state (98th percentile; extreme outlier), while U0003 ranks #3 of 108 in-state (98th percentile; typical, unremarkable volume for that code). This pattern points to a particularly strong market position for definitive drug testing and COVID specimen collection within the state.
Service-level details reinforce operational capabilities: the presence of large G0483 revenue ($1.5M Medicare; $1.9M Medicaid) and high claim counts for nucleic acid tests (e.g., Medicare 87798 with 155.7K claims and Medicaid U0003 with 99K claims) signals capacity for both complex toxicology (GC/MS, LC/MS) and very high-throughput molecular workflows. The payer-specific pricing differences and volumes also imply the lab balances lower-paid, very-high-volume Medicaid/Medicare COVID testing with higher-paid definitive testing.
The provider has been enumerated since 2014-01-15 (~12 years ago), and its lifetime Medicare and Medicaid revenues ($21.5M Medicare and $14.5M Medicaid) together reflect a sizable, established laboratory operation. Given the concentration in a few molecular and COVID/drug-testing codes and the extreme-outlier national/state rankings on several items, analysts should monitor code-level volume trends and payer policy changes as primary risk factors for near-term revenue variability.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
82 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 155,690 | $30 | $5.3M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 137,390 | $30 | $4.7M |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 157,700 | $10 | $1.9M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6,060 | $240 | $1.5M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 14,760 | $70 | $1.1M |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 12,700 | $30 | $431.7K |
| G0452 | Molecular pathology procedure; physician interpretation and report | 12,230 | $30 | $416K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 12,120 | $30 | $412K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 11,820 | $30 | $401.9K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 11,720 | $30 | $398.6K |
Showing 1–10 of 82
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 82 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
82 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87150 | 1 | 10 | 70 | $30 | $1.6M |
| 87798 | 1 | 10 | 650 | $30 | $553.2K |
| 87532 | 1 | 10 | 8,120 | $30 | $279.2K |
| P9603 | 6 | 10 | 139,860 | $1 | $213.5K |
| G0483 | 1 | 20 | 290 | $240 | $196K |
| U0003 | 1 | 10 | 230 | $70 | $166.6K |
| 87506 | 1 | 10 | 600 | $260 | $154.8K |
| 81419 | 1 | 10 | 40 | $2,400 | $105.6K |
| P9604 | 3 | 10 | 90 | $10 | $97.3K |
| 87496 | 1 | 10 | 80 | $30 | $94.8K |
Showing 1–10 of 82
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
83 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 98,960 | $50 | $5.3M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 19,820 | $100 | $1.9M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 50,720 | $20 | $963.7K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 10,420 | $90 | $948.1K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 16,520 | $50 | $809.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 26,300 | $30 | $657.4K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 9,320 | $40 | $363.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 33,760 | $10 | $337.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6,180 | $40 | $247.1K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 2,760 | $60 | $165.6K |
Showing 1–10 of 83
How this provider's Medicaid billing volume and revenue compare to other Arizona providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Arizona median
83 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3 | 110 | 960 | $70 | $1.7M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 2 | 40 | 190 | $30 | $662.3K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 20 | 160 | $90 | $459.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 15 | 170 | 3,560 | $30 | $397.9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 16 | 60 | 1,000 | $40 | $331.5K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 16 | 100 | 1,040 | $20 | $327.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 16 | 100 | 1,120 | $10 | $311.4K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 3 | 50 | 200 | $20 | $305.7K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 20 | 1,050 | $80 | $244.1K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 9 | 40 | 390 | $160 | $239.5K |
Showing 1–10 of 83
Other providers in the same ZIP code as Genetic Technological Innovations, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Lifetree Inc. | AZ | Home Health Agency | $0 | $117M |
| Theraplay4kidz, LLC | AZ | Occupational Therapist | $0 | $47.1M |
| Southwestern Eye Center Ltd | AZ | Ophthalmology Physician | $0 | $15.9M |
| Flor Fimbres | AZ | Nurse Practitioner | $8.5M | $0 |
| Deborah Dugan | AZ | Family Nurse Practitioner | $2.9M | $0 |
| Hermes Health Labs | AZ | Clinical Medical Laboratory | $1.2M | $1.3M |
| Myrna-leticia Rivas | AZ | Family Nurse Practitioner | $2M | $0 |
| Christopher Dwiggins | AZ | Medical Physician Assistant | $1.3M | $0 |
| Robin Ross | AZ | Retina Specialist (Ophthalmology) Physician | $720.8K | $0 |
| Genevieve Egnatios | AZ | Dermatology Physician | $674.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.